Mimedx Group Inc   (MDXG)
Other Ticker:  
Price: $8.1600 $-0.04 -0.488%
Day's High: $9.0394 Week Perf: -0.49 %
Day's Low: $ 8.10 30 Day Perf: 2.9 %
Volume (M): 2,091 52 Wk High: $ 9.27
Volume (M$): $ 17,059 52 Wk Avg: $6.61
Open: $9.00 52 Wk Low: $3.08

 Market Capitalization (Millions $) 1,284
 Shares Outstanding (Millions) 157
 Employees 904
 Revenues (TTM) (Millions $) 321
 Net Income (TTM) (Millions $) 58
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 3

Mimedx Group Inc
MiMedx Group Inc is a leading biopharmaceutical company that develops and markets innovative regenerative biologics and biomaterial products. The company specializes in the research and development of advanced wound care products, tissue repair products, and human placental tissue-based products designed to promote healing and tissue regeneration.

Founded in 2008, MiMedx Group Inc is headquartered in Marietta, Georgia, USA, with additional operations in Europe and Asia. The company has grown to become a leading provider of advanced wound care products and regenerative biologics with its proprietary platform technology, Purion. These products are designed to provide a safe, effective, and cost-efficient solution to treat chronic wounds, surgical wounds, and other tissue injuries.

MiMedx's Purion platform technology allows for the creation of human placental tissue-based products that can be implanted to promote healing and tissue regeneration. The company's portfolio of products includes AmnioFixe and EpiFixe for advanced wound care and surgical applications, Purione for tissue repair and regeneration, and OrthoFloe for orthopedic applications.

AmnioFixe and EpiFixe are MiMedx's flagship products, which are derived from human amniotic membrane tissue. Both products are used to treat chronic and acute wounds, such as diabetic foot ulcers, pressure ulcers, venous leg ulcers, and surgical wounds. The products contain natural growth factors and other bioactive molecules that promote healing and tissue regeneration.

Purione is a new line of tissue repair and regeneration products that is expected to drive future growth for MiMedx Group Inc. This technology platform allows the processing and sterilization of human tissue to produce purified extracellular matrix (ECM) that can be used to repair, regenerate, and remodel tissue defects, such as bone, cartilage, and soft tissue.

OrthoFloe is MiMedx's newest product line that is designed to enhance the healing of orthopedic injuries and surgical procedures. This product is derived from human amniotic fluid and contains growth factors and other natural products that are beneficial for bone and tissue repair.

In addition to these products, MiMedx Group Inc also offers a range of training, education, and support services to healthcare professionals to ensure that their products are used effectively and safely. The company also works closely with healthcare providers to develop customized treatment plans and clinical protocols to ensure optimal patient outcomes.

MiMedx Group Inc is committed to advancing the field of regenerative medicine by developing and commercializing innovative products that improve patient outcomes, reduce healthcare costs, and enhance quality of life. With its proprietary technology platform and extensive product portfolio, MiMedx is well-positioned for continued growth and success in the years to come.

   Company Address: 1775 West Oak Commons Court, NE Marietta 30062 GA
   Company Phone Number: 651-9100   Stock Exchange / Ticker: NASDAQ MDXG


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Mimedx Group Inc

Tax Adjustments Boost Earnings by $37.52 Million for Mimedx Group Inc

Mimedx Group Inc, a leading Medical Equipment & Supplies company, has recently released its financial results for the October to December 31, 2023 period. The results showcase a positive trajectory in terms of income, EPS, revenue growth, and improved profit margins. Additionally, the company's successful debt refinancing and improved capital structure highlight their dedication to strengthening their financial foundation. This article examines the impact of these developments on the company's future prospects.
1. Positive Income Growth and Elevated EPS:
Mimedx Group Inc reported a significant improvement in its income, turning positive at $0.24 per share compared to a negative $0.02 per share in the previous year. Moreover, the EPS more than doubled by 307.14% from $0.06 per share in the prior reporting season. This substantial growth in income and EPS demonstrates the company's ability to generate profits and indicates positive momentum for the future.

Financing Agreement

Mimedx Group Inc Secures New Credit Facilities for Interest Savings and Capital Support Amidst Cumulative Net Loss

Published Mon, Jan 22 2024 1:01 PM UTC

In a recent announcement, Mimedx Group Inc revealed that it has successfully obtained new credit facilities, offering substantial interest savings and access to additional capital. The company aims to utilize these new resources to support the execution of its strategic priorities. This development comes in light of Mimedx Group Inc recording a cumulative net loss ...

Mimedx Group Inc

Mimedx Group Inc. Achieves Remarkable Turnaround with Double-Digit Top-Line Growth in Q3 2023

The stock market has been on a rollercoaster ride recently, with ups and downs that have left investors feeling uncertain. But there is one company that is bucking the trend and delivering impressive results: Mimedx Group Inc.
In the third quarter of 2023 earnings season, MDXG reported a significant improvement in its bottom-line. Its earnings per share rose to $0.06, compared to a loss of $-0.09 a year ago. This is a remarkable turnaround for the company and is a testament to its strong leadership and strategic decisions.

Mimedx Group Inc

Mimedx Group Inc Posts Stirring $81.26 Million Revenue for Q2 2023, Resilient Amid Medical Equipment Sector Fall

Mimedx Group Inc, a leading Medical Equipment & Supplies company, has displayed a strong upward trend in its stock performance over the past five days and an exceptional growth rate of 168.35% in 2023. However, despite a surge in revenue, the company reported balanced books with no earnings per share in the second quarter. This article will analyze these financial results and question how they might impact Mimedx Group Inc going forward.
1. Revenue Growth and Positive Surprises:
Mimedx Group Inc experienced a remarkable 21.491% jump in revenue to $81.26 million in the second quarter of 2023, compared to the same period last year. This top-line growth is particularly surprising considering the average revenue decline of the Medical Equipment & Supplies sector, which declined by -0.01%. Furthermore, the sequential revenue advancement of 13.367% from $71.68 million is another positive indicator of the company's performance.

Mimedx Group Inc

In spite of the boost in revenue Profitability not Reached by the MDXG during the financial interval closing Mar 31 2023

Mimedx Group Inc. has announced that it has experienced an upturn in revenue for the financial interval ending March 31, 2023. Their revenue has surged by 21.703% to $71.68 million from the same reporting season a year earlier. Despite this increase in revenue, the company has reported a net loss of $-0.06 per share. This is an increase in loss from $-0.02 per share in the previous quarter.
Unfortunately, the company has also experienced a decline in revenue, which has decreased by -3.629% from $74.38 million. These results indicate that Mimedx Group Inc. has a long way to go before it can return to profitability. However, investors should take some comfort in the fact that the company's net loss of $-6.667 million in the financial first quarter of 2023 is a significant improvement over the $-12.075 million deficit from the same reporting season a year earlier.


Mimedx Group Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Mimedx Group Inc does not provide revenue guidance.

Earnings Outlook
Mimedx Group Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com